HISTORICAL ASSOCIATION BETWEEN PML AND JCV
Progressive multifocal leukoencephalopathy (PML) is the only demyelinating disease in the human brain in which the basis for the neurological disorder is a well-characterized etiological agent, the human polyomavirus JC virus (JCV), which causes lytic infection of the myelin-producing oligodendrocyte. Although the simian polyomavirus simian virus 40 (SV40) has been implicated in several reports of PML (222, 223) , these isolates have not been well characterized. Reexamination of some of these cases by in situ DNA hybridization has revealed JCV in the brain tissues (195) .
Several major elements in this infectious neurologic dis- (15, 38, 228) . These clinical histories and descriptions of findings at autopsy were consistent with the development of a multifocal distribution of small or confluent white matter plaques in the cerebral hemispheres, basal ganglia and thalamus, cerebellum, and brain stem. The cause of these lesions was not known. The suggestion that a virus might be involved in the pathogenesis of PML came in 1959, when inclusion bodies were seen in the nuclei of damaged oligodendrocytes (34) . Several years later, Richardson reported an additional 10 cases of PML in elderly patients and others with underlying diseases such as lymphomas, leukemias, sarcoidosis, and cancer (172) . He noted that the distribution of the plaque lesions was consistent with an atypical virus infection. As the pathology of PML became more widely recognized, electron microscopic evidence revealed particles resembling polyomavirus present in the enlarged nuclei of oligodendrocytes with inclusion bodies (234, 235, 237) . Attempts to isolate the suspect virus were not successful until 1971, when brain tissue from a patient with PML was used as a source inoculum in cell cultures derived from human fetal brain. Padgett and her colleagues (161) isolated a human polyomavirus from long-term cultures made up mostly of glial cells. The successful isolation of virus using human fetal brain tissue in primary cultures was the first direct indication that a new "neurotropic" viral agent was associated with the occurrence of PML. The viral architecture (nonenveloped icosahedron) and size, diameter of 40 nm, were similar to those of another virus isolated from a renal transplant patient that was reported at the same time by Gardner et al. (69) . Both viruses were named with the initials of the donor patient, i.e., JCV for the patient whose brain was infected with virus and BK virus (BKV) for the renal transplant patient whose urine contained the isolate. Both viruses were also associated with immunosuppressive conditions: most frequently, neoplastic diseases in PML patients with JCV and drug therapy to prevent graft rejection in renal allograft recipients with BKV infection (40) . Although both viruses were eventually found in the urine, BKV has been detected far more frequently than JCV in the urine (10, 11, 20, 113) but has never been found in the brain of PML patients.
Unlike the simian polyomavirus SV40, these viruses share the property of hemagglutination of human type 0 erythrocytes (69, 129, 157) . This property has allowed a seroepidemiological survey for viral antibody in patients suspected of infection and in the population as a whole. The seroepidemiological data generated in the mid-1970s using hemagglutination inhibition assays indicated that JCV and BKV were different viruses (67, 68, 156, 157) , were distributed worldwide (29) , and were present in most of the population, with serum conversion occurring at an early age (178, 217) . Immunoglobulin G (IgG) antibody directed against JCV was most often demonstrated and was present in the healthy population, including pregnant women (9, 47) . Most PML patients were found to have preexisting antibody in JCV and did not show a rise in antibody titer during the progression of PML. The lack of IgM antibody in the serum and cerebral spinal fluid (CSF) of many seropositive patients suggested reactivation of a latent infection (28, 158, 217) . The epidemiological data along with the characteristic of an underlying immunosuppression for the emergence of PML pointed to the ability of JCV and BKV to establish latent infections. This inferred pathogenesis still holds true 20 years after the isolation of these viruses. The fact that JCV was unique among other members of the genus Polyomavirus was soon established by its biological, molecular, and genetic characteristics.
BIOLOGY OF JCV Human Brain Cultures and Virus Growth
The isolation and growth of JCV in human fetal brain cultures in 1971 (161) allowed additional virus isolations from PML-affected tissue. Over the next several years new JCV isolates (159) helped link the etiology of PML with this new species of human polyomavirus (224) . Because these first isolations were reported from the University of Wisconsin in Madison, the isolates were serially designated Mad-1 (the prototype), Mad-2, etc. However, the necessity of using human brain cells for successful isolation and growth immediately raised questions about the host range of JCV and began the identification and description of JCV as a new human neurotropic agent. Since this label has been applied to JCV, it has been difficult to alter the concept that JCV multiplies only in human brain. The seroepidemiology of JCV, however, suggested that infection with JCV is common and perhaps recurrent in individuals worldwide. A locus of initial infection in cells more accessible than those of the central nervous system (CNS) appeared likely.
Consequently, the paradox arose of how JCV could be such a prevalent virus in the population and yet appear to infect only a highly specialized neuroglial cell, the myelinproducing oligodendrocyte, and cause a rather poorly recognized demyelinating disease in a select population of patients with underlying immunosuppression. This paradox began to be resolved with the testing of other cell types for susceptibility to JCV.
The initial description of the growth of JCV in primary human fetal brain cultures identified the spongioblast, a bipolar process-bearing cell that was considered the precursor of the oligodendrocyte, as the most susceptible cell (156, 188) . The other cell type in these cultures was the astrocyte, which makes a bed layer of strongly adherent cells on which the oligodendrocyte precursors grow (56, 101) . These two kinds of cells are the glial cells that constitute the white matter. Multiplication of JCV in this heterogeneous population of cells required many days to weeks before substantial amounts of virus could be harvested, and only subtle cytopathic effects were evident (124, 156) . Quantitation of virus was done by using the virion's ability to agglutinate human type 0 erythrocytes. The data describing the amount of JCV were given in hemagglutination units, usually expressed in logarithmic notation. JCV is an extremely cell-associated virus even after final virion assembly in the nucleus. Consequently, no suitable plaque assay has ever been developed. Very little virus is shed into the cell culture medium. Harvesting of JCV from infected cell cultures, therefore, requires multiple steps of physical disruption such as freezethaw as well as chemical treatment with sodium deoxycholate (155) . Hemagglutination still remains the most reliable method of quantitating JCV, and hemagglutination inhibition is the only assay used to test for the presence of antibody. reported as negative for JCV Mad-1 growth, as were monkey kidney cell lines such as BSC-1, CV-1, and Vero cells (156) . After weeks of culture and subculture, only a few T-antigenpositive cells were found in human kidney tissue. To determine whether host cell restriction was at the level of virion adsorption and penetration, JCV DNA was used to initiate infection by transfection. Four JCV isolates and their DNAs were tested on human embryonic kidney and lung cells with human fetal glial cells as the positive control (65) . Only DNA derived from the Mad-4 strain demonstrated some ability to produce the viral early T protein and late capsid protein.
DNAs from the other isolates were infectious for glial cells but no others. Consequently, the restricted growth of JCV in other cell types appeared to be dependent not on receptor recognition (adsorption) but on intracellular factors controlling early transcription and replication. A number of other studies documented JCV T-protein production in human vascular endothelial cells (58) , human amnion (96, 202) , and urine-derived epithelial cells, which also produced small quantities of virus and could be used to isolate JCV excreted in the urine (18) .
The limited success of viral synthesis in human embryonic kidney cells (145) was consistent with the detection of JCV in the urine of PML-affected and renal transplant patients and of pregnant women (216) . Inoculation of prototype strain Mad-1 in human embryonic kidney cells with subsequent serial passage resulted in an adapted JCV, which was termed JCV-HEK (145) . The ability of this adapted virus to grow well in kidney cells resulted from substantial genome deletions and rearrangements in the noncoding sequences of the viral regulatory region (143, 232) . This strain appeared as a laboratory artifact of virus subculturing since JCV with a similar sequence in PML tissue has never been identified. This experience provided additional evidence for the role of noncoding regulatory sequences as controlling elements in determining host range. As will be discussed in more detail below, the JCV genome sequences of virus isolated from kidney tissue substantially differ from those of virus isolated from brain tissue (51, 117, 231) . These experiments, however, emphasized the fact that JCV grew best in cultures of human glial cells usually derived from fetal brain and, less frequently, adult brain (4, 230) .
Development of Astrocyte Cell Lines
Human fetal glial cells are still the most sensitive and most susceptible host for the study of JCV in laboratory cultures. The availability of the primary tissue and the time required for adequate growth and use of these cells severely limited many experiments. To help alleviate this problem, a human fetal glial cell line (SVG) was produced by immortalization of astrocyte cells with a replication-defective SV40 DNA clone that expressed high levels of the SV40 T protein (124) . This cell line proved to be susceptible to JCV infection. A similar method was used to produce a human kidney cell line (SV1). The SV1 cells, however, were not susceptible to JCV infection (123) . Attempts to immortalize the oligodendrocyte precursor cell, which does not divide rapidly in culture, were not successful. Shortly after the description of the SVG cells, another susceptible human fetal glial cell line (POJ) was produced by using replication-defective JCV DNA expressing the JCV T protein (131) . The establishment of the SVG cells as astrocytes, not derived from the "spongioblast" precursor cell, and their continued susceptibility to JCV led to a closer examination of the cell types in human fetal brain cell cultures (56) and their relative susceptibilities to JCV infection.
Both the astrocyte and the precursor cell of the oligodendrocyte allowed JCV growth at passages well beyond primary cultures (127) . Because of their increased mitotic activity, astrocytes could produce more JC virions than the previously described spongioblasts and showed no evidence of genome alterations. The identification of JCV-infected astrocytes from PML-affected brain tissue placed in culture confirmed the susceptibility of this glial cell type to JCV (140, 180) . Some of the cells in human fetal brain cultures that were described as spongioblasts (156, 215) have been recently identified as neurofilament-containing neurons (194) . Their short lives and senescence in JCV-inoculated cultures could be the result of neuronal cell death caused by the lack of stimulation from nerve growth factor (194) rather than the result of infection by virus. These process-bearing cells in human fetal brain cultures do not become infected with JCV, which is consistent with the fact that JCV-infected neurons have never been found (78) . Recent (218, 236, 238) . T (218) . The Mad-2 and Mad-4 strains produced a high incidence of tumor development, with Mad-4 virus predominantly causing pineal gland tumors (160) . Intraocular inoculation of virus in hamsters resulted in abdominal neuroblastomas that metastasized to the liver, bone marrow, and lymph nodes (213) . Neuroblastomas and medulloblastomas were also found in animals inoculated subcutaneously and intraperitoneally (238) . Hamster either SV40 or BKV never developed tumors but did demonstrate antibodies to these viruses (219) . Most of the tumors that resulted from JCV inoculation were described as glioblastoma multiforme grade IV or astrocytomas occurring 18 to 32 months after inoculation (141) . Figure 2 shows the appearance of such a tumor on necropsy of an inoculated owl monkey 22 months after virus inoculation. The JCV genome was randomly integrated in the tumor tissue, frequently as multiple tandem copies, but was not found in nontumor tissue in the brain (142) . One novel transplantable owl monkey astrocytoma (Owl 586) that spontaneously released infectious JCV in cell culture was found (128) . The cell cultures of Owl 586 produced a large amount of JCV T protein compared with other owl tumor cells analyzed by immunoprecipitation (125) . The Owl 586 T protein was also able to complex with the primate cellular p53 protein. The complex could not be demonstrated in other monkey tumors or cultured cells from them. Several mouse monoclonal antibodies made to the SV40 T protein were found to cross-react with the JCV T protein in monkey or hamster tumors in those regions of homology near the amino terminus of these proteins (125, 128, 196) . Even though JCV induces glioblastomas in nonhuman primates and gliomas have been described in PML patients (32, 190) , there is no evidence as yet for an association between JCV and human tumors of the nervous system (53) .
JCV in Transgenic Mice
Another approach to developing an animal model for the acute demyelination seen in PML-affected brain tissue was the use of transgenic mice. The regulatory and coding sequences for the JCV early T protein were injected into one-cell mouse embryos to generate founder mice (191, 192) . Two male founder mice that contained the JCV early region survived to maturity to produce offspring. Approximately 20 to 50% of these offspring contained an intact JCV early region. Some of the offspring demonstrated a mild to severe tremor, which was evident when the mice were in motion. A similar phenotype had previously been observed in myelindeficient strains of the quaking and jimpy mice (89, 189) . In the offspring inheriting the intact JCV early region and exhibiting the tremor, a dysmyelination had occurred in the CNS but not in the peripheral nervous system. High levels of the JCV T-protein mRNA were found in the brains of these myelin-deficient mice. Transgenic mice with the early region of BKV, on the other hand, developed liver and kidney tumors (192) . BKV T protein was expressed at low levels in brain, heart, and lung tissues but at high levels in muscle and liver tumors.
To further characterize the dysmyelination in the JCV transgenic mice, Trapp et al. (209) examined the expression of the JCV and myelin-specific genes. An initial study of the brain of JCV transgenic mice revealed an absence of myelin sheaths, although the numbers and diameters of axons did not appear to be reduced. In addition, the levels of myelin basic protein (MBP), proteolipid protein (PLP), and myelinassociated glycoprotein were reduced in the brains of the transgenic mice; however, the expression of PLP and MBP genes appeared to be normal. Since the JCV T-protein gene appeared to be expressed in the same region of the brain as the MBP gene, it was suggested that expression of the JCV T protein altered the levels of proteolipid and myelin basic protein syntheses and the maturation of oligodendrocytes. The mechanism of dysmyelination remains unclear, but there is evidence for the appearance of JCV T protein in (155) . Orientation at its single EcoRI restriction endonuclease cleavage site and alignment with SV40 and BKV DNAs following additional digestions revealed that the JCV DNA was unique (112, 134, 135, 155, 170) . The first region of the genome to be sequenced was the putative origin of DNA replication, which was compared with that of SV40 (63, 144) . Subsequently, the entire sequence of the Mad-1 genome was determined, thus allowing extensive comparisons with SV40 and BKV for function and regulation (64) . Analysis of the nucleotide sequence divides the JCV genome into three functional regions: (i) the early region on the proximal side of the replication origin, (ii) the late region located on the distal side of the replication origin, and (iii) the noncoding or regulatory region between the early and late regions (Fig. 3) appears to facilitate the transformation event (146) , especially when the concentration of the T protein is limited (22) . The small t protein of JCV has been identified in transformed hamster cells (66) but not in lytically infected human glial cells (126) or in monkey tumor cells (125, 128) . The open reading frames for both proteins appears to begin at nucleotide 5013, but a differential splicing event generates two mRNA species for the T and t proteins (64) . A translation termination signal for the small t protein is found at nucleotide 4495, while the termination signal for the T protein is at nucleotide 2603. Therefore, the T and t proteins share the same 5' ends but each contains unique 3' ends. These early open reading frames encode a 688-amino-acid T protein and a 172-amino-acid t protein. The size of the JCV large T protein as determined by migration in sodium dodecyl sulfate-polyacrylamide gels ranged from 83 to 96 kDa (23, 84, 126) . These analyses also demonstrated degradation products of the T protein, suggesting its relative instability compared with that of the SV40 T protein.
The late-region sequences are transcribed clockwise from the opposite strand relative to the early genes and, by analogy with SV40, appear to encode four proteins (64) . At the 5' end of the late region is the smallest open reading frame which could encode a polypeptide of 71 amino acids. In SV40, the open reading frame in the leader region encodes a 7.9-kDa protein called the agnoprotein since its function is not known (26) . This agnoprotein can bind DNA (98) and may be involved in the viral maturation pathway (94) . The largest open reading frame is located near the 3' end of the late region and encodes the 354-amino-acid VP1 capsid protein, which is the major structural protein functioning in cell adsorption. Between the 5' and 3' open reading frames of the agnoprotein and VP1 proteins are two other open reading frames that encode the VP2 and VP3 capsid proteins (344 and 225 amino acids, respectively). The smaller of these two open reading frames, VP3, is a subset of the larger VP2. The number and sizes of the late proteins of JCV have not been analyzed as well as those of the T protein. However, antisera to the capsid proteins have been used to study late gene expression (65, 66, 145, 149, 198) . Using immunocytochemistry, for example, Stoner et al. (197, 198) found only the T protein in brain tissues in which the capsid proteins could not be detected. The lack of capsid proteins in these tissues was interpreted as an indication of an abortive or latent infection.
The regulatory region comprises noncoding sequences that lie between the early and late genes. It contains the origin of DNA replication and the cis-acting signals for both early and late transcription (63, 64, 144) . A comparison of the nucleotide sequence encompassing the JCV replication origin with those of SV40 and BKV revealed extensive areas of homology (Fig. 4) . The presence of two regions of dyad symmetry and a 17-bp palindrome shared by all three viruses reflects the similarities of the organization within this structure. In one region of dyad symmetry, 22 or 23 nucleotides are identical in all three polyomaviruses. In SV40, this latter region contains one of the large-T-protein binding sites (site I), while the second large-T-protein binding site (site II) overlaps the 17-bp palindrome (148) . A third large-T-protein binding site present in SV40, however, does not appear to be present in JCV. Binding studies with a hybrid adenovirus-SV40 large T protein demonstrated that it binds to a region of the JCV genome that contains the origin of DNA replication (63) .
Besides the origin of DNA replication, there are two 98-bp tandem repeats located on the late side of the noncoding sequences (Fig. 5) . Although the organization of the nucleotides in this region of JCV resembles that in SV40 and BKV, there is little sequence homology within the repeat units. The regulatory sequence of the Mad-1 strain of JCV differs from other regulatory sequences in that it has its TATA Goldberg-Hogness box as part of the repeat units. This box is the sequence required for positioning the start site of mRNA synthesis in many genes (73, 75) . Each TATA sequence is located on the early side of the individual 98-bp tandem repeats. However, the second TATA box distal to the DNA origin is deleted in many naturally occurring JCV isolates and does not appear to be necessary for virus multiplication (120, 136) or to contribute to the DNA tertiary structure (8) . The cis-acting nucleotide sequences within these 98-bp repeats have been the focus of much experimental attention as crucial elements in explaining the tropism of JCv.
Alterations in the Viral Genome
Since the first isolation of JCV from brain tissue, the genome has appeared to be heterogeneous in size (65, 79, 95, 135, 145, 155 (132) are shown above the first 98-bp repeat unit. Nucleotides protected from DNase I digestion by the nuclear protein NF-1 are indicated by the heavy straight line. The heavy arrow at the beginning of the nucleotide sequences signifies a major start site for early-mRNA synthesis (106) . Dots over the nucleotides denote the locations of the origins of DNA replication (64, 120) . The ATG boxed at the end of the nucleotide sequence is the putative translational start site for the agnoprotein.
source of the JCV genome and the derivation of a molecular clone (57, 79, 80, 138, 170) , and (iii) the natural genetic variation of the isolate (137) . Alterations in the JCV genome were seen in JCV strains that have been cloned directly from tissue specimens (117, 138) and have not been previously propagated in tissue culture. Although the genomes of these different isolates were not identical, each appeared to be homogeneous. This lends support to the possibility of a natural genetic variation in strains of JCV that could appear in vivo as well as in vitro.
Genomes of JCV found in the urine of non-PML-affected elderly individuals, with no specific signs of immunodeficiency, demonstrated a genotype that contained a 23-bp insertion (see Fig. 5 for detail) that had been previously described in some JCV isolates from PML-affected brain tissue (137) . This 23-bp insertion is not found in the Mad-1 strain. A 66-bp insertion between base pairs 80 and 98 of the tandem repeat (231) was also found in these JCV genomes. The sequence arrangement that included both the 23-and 66-bp insertions, in comparison with the Mad-1 strain, was suggested as an "archetypal" genome from which other JCV genomes found either in kidney or brain, for example, may have been derived by alterations and deletions. In fact, the genome of JCV from the kidney of a PML-affected patient contained a sequence arrangement similar to the archetype (117) . Polymerase chain reaction (PCR) amplification of JCV regulatory sequences recovered from the urine of AIDS patients and bone marrow transplant recipients also demonstrated the archetypal sequence (61) . However, sequences of urine-derived JCV isolates from other bone marrow and renal transplant patients showed no differences from those of the Mad-1 strain found in the brain (147) .
Most changes in the genome have been located in these regulatory sequences, with the most notable being the deletion of 19 bp in the second tandem repeat. This deletion eliminates the duplicated TATA box and was first described in the Mad-4 strain (136) . A similar genotype was found in several other brain isolates (Her-1, Mad-7, Mad-8, Mad-9, and Mad-11 [136] , a strain from Tokyo [138] ) and the virus released from the owl monkey astrocytoma (128) . In addition to this 19-bp deletion, there is a 23-bp insertion of purine-rich sequences ( Fig. 5 ) between nucleotides 36 and 37 of the Mad-1 strain in the first 98-bp tandem unit (5'-TAGGGAG GAGCTGGCTAAAACTG-3'). These sequences may represent a functional counterpart (136) to the 21-bp repeats in SV40 that are binding sites for transcription factor Spl (25) . The Tokyo strain also has a 20-bp insertion between the first and second repeat units that is almost identical to a sequence found at the 5' end of the agnoprotein region.
The functional significance of these alterations in the pathogenesis of PML is still unclear. However, the sequences of the JCV isolates from the kidney and brain of one PML patient (117) raised the following interesting point. The coding sequences of the two isolates appeared identical, which suggested that these viruses arose from a single strain. The noncoding sequences, however, demonstrated extensive and varied alterations. In the regulatory region of the brain isolate, the tandem 98-bp repeats found in the Mad-1 strain have been truncated at the 3' end of the repeats, although they are still tandemly arranged (two repeats of 63 bp each). Between these two sets of repeating units there was a 12-bp insert almost identical to an insertion found in the 3' end of the second 98-bp repeat unit of the Mad-8a isolate (136) . The first of the 63-bp repeats contained the 23-bp insertion found in the regulatory region of some JCV Mad isolates, while the second repeat had lost the TATA sequence and contained only 16 of 23 bp of the insertion found in the first repeat. The brain isolate also has a 93-bp tandem repeat unit closely following the first 63-bp tandem repeats which includes a duplication of 69 bp. The kidney isolate, on the other hand, shared some features with the isolate from the brain. It had only one copy of the Mad-1 98-bp repeat unit, with several insertions that resembled the archetypal sequence (231) . The kidney isolate also had short sequences inserted in its 98-bp repeat unit that resembled SV40 and adenovirus ElA core enhancer elements (64) and sequences from the JCV-HEK strain. There are a number of differences in the coding sequences between the kidney and brain isolates, but usually most of them do not alter the amino acid composition. In 10 isolates from brain tissue of PML patients, small variations were reported in the capsid protein sequences (80 It should be noted that JCV DNA sequences are usually compared with the sequence derived from the first JCV isolated, Mad-1, which has been considered the prototype strain. New data on other strains or isolates indicate that the Mad-i strain may be atypical. Also, it is still unclear whether viral replication in brain or kidney tissues, for example, results in selection of a strain trophic for each tissue or whether there is an archetypal strain that fosters the virus that finally enters the nervous system. Dynamic alterations of JCV DNA perhaps during multiplication in host tissues has added another degree of challenge in determining the critical factors controlling the glial cell tropism and the pathogenesis of JCV.
Expression of the Viral Genome
The physical description of the JCV genome helped researchers design experiments to determine the functional significance of the noncoding sequences. In studies directly testing the regulatory sequences for host range control, Kenney et al. (104) examined the ability of the 98-bp tandem repeats to act as a promoter-enhancer to stimulate synthesis of the chloramphenicol acetyltransferase (CAT) gene. Two important observations were made. First, the regulatory region was able to stimulate the expression of CAT when the region was cloned in an orientation with the first TATA sequence proximal to the CAT gene. Second, this stimulation appeared to be relatively cell specific, 20-fold higher in human fetal glial cells than in HeLa cells and 7-fold higher than in CV-1 cells. The promoter-enhancer sequences of SV40 and BKV showed significant activity in most cells tested (76, 177) . In HEK cells, the JCV regulatory sequences produced only minimal levels of CAT, reflecting the very limited ability of JCV to propagate in kidney cells. When the orientation of the promoter-enhancer sequences was reversed, CAT activity was still highest in human fetal glial cells. The tissue specificity and low activity exhibited by the regulatory sequences were confirmed by others (60, 200) .
In a series of studies set to determine which nucleotides influence the lytic and transforming properties of JCV in cell cultuires, hybrid genomes of JCV and SV40 and of JCV and BKV were constructed (23, 39, 84) . In one study (39) in which the regulatory region of JCV was replaced with that from either SV40 or BKV, the new hybrid constructs were not viable in human fetal glial cells. In the reverse hybrid constructs, however, the regulatory region of JCV drove synthesis of either the SV40 or BKV T proteins in human fetal glial cells. These results suggest that SV40 and BKV T proteins could positively interact with the JCV regulatory sequence but that JCV T protein, although shown to bind the SV40 DNA, could not functionally substitute for the homologous T protein. Along this line of experimentation, researchers constructed hybrid T-protein viruses that demonstrated (23, 84 ) that JCV T protein was also weak in its ability to induce transformation. From these data, it appeared that the JCV T protein played a significant role in determining efficient gene expression in a cell-type-specific manner.
In another study, JCV regulatory sequences were altered following transfection of a DNA construct that placed the SV40 21-bp triplicates and the 72-bp repeats at the distal end of the JCV 98-bp repeats that did not interrupt the coding sequences for the JCV T protein or the capsid proteins (211) . A series of cell-induced deletions were made following transfection of the constructs into either human fetal glial or embryonic kidney cells. An infectious viable virus was isolated with a regulatory region that contained almost one complete 98-bp repeat from JCV and one and one-third SV40 72-bp repeats. The other JCV 98-bp and the SV40 21-bp triplicates were consistently deleted whenever transfections were started with the parent construct. This virus produced JCV T protein that was not altered except that its concentration was higher than that of prototype JCV T protein in human fetal glial cells. The host range of this chimeric virus was expanded to include lytic activity in human and simian kidney cells, but it remained restricted to primate cells for growth (211) . These data suggested that the JCV regulatory sequences were responsible for the host range phenotype and the glial cell tropism. Although still a subject for experimentation, the regulatory region sequence for JCV does appear to be the predominant factor in controlling growth properties of JCV.
Nuclear DNA-binding proteins that interact with these sequences are being identified as important proteins for transcription. Nuclear (25, 150) . Further analysis will have to be performed to determine whether the TACCTA or any other cis-acting sequence is involved in specifying the start sites for late transcription. The influence of the T protein on late transcription and the number and exact start sites for late mRNA remain to be determined.
Replication of the Viral Genome
When the nucleotide sequence of the JCV genome was established, the sequences for the origin of DNA replication were easily recognized by their homology to the sequences of other polyomaviruses (Fig. 4) (64) . The sequences responsible for T-protein binding to the ori region resemble those of SV40 DNA. Early experiments demonstrated that the SV40 and JCV T proteins did bind to at least two of the three sites with the sequence GAGGC (63) . A third site present in SV40 may not be required for JCV replication. Unlike the efficient and rapid multiplication of SV40, JCV DNA replication could not be detected until 3 to 5 days following infection, after which time it continued for several weeks (60, 106) . Even in many human glial cells in which the JCV T protein is present, replication does not begin or cannot be detected for several more days (124) . The necessity of a functional JCV T protein was demonstrated by Mandl et al. (131) by showing that JCV could not replicate when there was a mutation in the coding sequences for T protein. It was also shown that the SV40 and BKV T proteins could functionally interact with the JCV ori sequences and result in a lytic infection (39) .
The cell type restriction for JCV growth had already been documented at the level of early transcription (60, 104) . However, there was yet another level of restriction for replication (60) . JCV DNA could replicate in immortalized primate cell lines that contained an SV40 T protein such as SVG (human glial), SV1 (human embryonic kidney), and COS-1 (monkey kidney) but not in HJC (hamster brain cells with expressing JCV T protein), CV-1 (monkey kidney), or HeLa. In these experiments, JCV replication occurred in HeLa and CV-1 cells only when the SV40 T protein was present. In the hamster cells, replication could not take place even in the presence of T protein. Conclusions drawn from these series of experiments were that primate cells contain necessary factors for replication when the T protein is present but that rodent cells do not. Therefore, it appeared that transcription of the JCV genome is restricted by cellspecific factors functioning best in glial cells and that replication is restricted by species-specific factors functioning best in primate cells (60) .
Recently, Lynch and Frisque (120, 121) determined that sequences to the late side (nucleotides 38 to 30 containing the repeat sequence AGGGA) of the second T-proteinbinding site on JCV DNA had a strong influence on the efficiency of JCV T-protein-dependent replication activity. This region in the regulatory sequences has been shown to adopt a non-B conformational tertiary structure (8) and to contain a binding site for NF-1 (6). Mutations introduced into this region by deletion or conversion greatly reduced the replication function of the JCV T protein. Its proximity to the A+T sequences in the exact ori site for initiation of replication suggested that the JCV T protein may require a particular DNA conformational structure to function effectively. In other experiments testing JCV DNA replication in a variety of cell lines, JCV T protein had a lower specific DNA binding activity than SV40 T protein and was generally much less efficient (111) . This inefficiency in driving replication may be due to weak interactions between the JCV T protein and its target DNA and to the need for the JCV T protein to interact with host cell proteins for replication to occur. Consequently, the restricted nature and unusually long duration of viral multiplication can be attributed in large measure to the replication machinery needed for successful viral multiplication. These elements include the viral T protein, the viral DNA sequences that are recognized by this protein, the conformational structure probably required for successful binding, and the cooperation exhibited by the protein factors in the appropriate host cell.
PML AS AN INFECTION OF THE BRAIN Pathology of PML
Following infection by JCV, oligodendrocytes undergo cytolytic destruction that results in loss of myelin. At its simplest, this is the central observation in understanding the pathology and subsequent clinical features of PML. The principal function of the oligodendrocyte is to myelinate the axons that project from the neuronal cell bodies of the overlying cortex. In gross sections, cortical neurons appear to be grey, hence the term cortical grey matter. In contrast, the underlying oligodendrocytes and their myelin sheaths appear to be white, and they are described as subcortical white matter. Both the cerebral hemispheres and the cerebellum are stratified in this manner. Lytic infection of oligodendrocytes in patients with PML can therefore be recognized as destruction and demyelination of the subcortical white matter.
Foci of demyelination initially are microscopic and asymmetrically distributed in space. As the disease progresses, areas of demyelination enlarge and these foci may coalesce, making them visible on gross examination in cut sections of the brain. In areas of active demyelination, there is a progressive attrition of oligodendrocytes from viral cytolysis, and while they may be found throughout the lesions, oligodendrocytes are more prominent at the borders of demyelinated areas (97) . Moreover, some of the remaining oligodendroglial nuclei may be two-to threefold larger than normal, may be strongly basophilic with effacement of the chromatin pattern, and may contain intranuclear inclusions (14, 172) . As seen by electron microscopy, the intranuclear inclusions consist of a dense array of crystalline and filamentous JCV particles (139, 234, 235). In both the cerebral and cerebellar hemispheres, viral DNA and antigen can also be detected by in situ hybridization and immunocytochemistry in what appear to be normal oligodendrocytes (91, 97) . These normal oligodendrocytes are most frequently seen in areas with no demyelination.
In addition to the oligodendroglial pathology, greatly hypertrophied giant astrocytes may be observed in areas of demyelination in 80% of cases (175) . These astrocytes are pleomorphic and sometimes described as bizarre. They have basophilic nuclei that frequently contain mitotic figures and are irregularly lobulated. While viral DNA can be detected in these astrocytes by in situ hybridization (2), they rarely express late viral proteins (3) . Although the morphology of the astrocytes suggests a neoplastic process, few cases of intracranial tumors have been associated with PML (32, 55, 74, 88, 172) . Reactive astrocytosis, a nonspecific finding in many neuropathological processes, is also seen with PML.
The demyelinated axon typically is spared in areas of demyelination, but rare neuronal loss in grey matter has been reported (114, 151) . Since some oligodendrocytes are found in the cortical ribbon as well as in the grey matter of the basal ganglion and cerebellum, infection of these cells then probably leads to demise of the adjacent neurons. Alternatively, loss of the myelin sheath leads to axonal injury and subsequent retrograde degeneration of the cell body in the grey matter. Neurons are not infected by JCV (13) . Neuronal death is probably secondary to an as yet unrecognized process. Some cases of grey matter involvement have been seen in brain cells coinfected with the human immunodeficiency virus (HIV), suggesting that HIVcaused encephalitis may further contribute to neuronal death.
In areas of demyelination, lipid-laden macrophages are frequently found in the center of the lesion, probably recruited into the CNS to phagocytize the myelin breakdown products. Detection of viral DNA in macrophages by in situ hybridization has not been reported. In some cases of PML associated with AIDS (see below), large numbers of HIVinfected macrophages are found in extremely extensive, necrotic lesions (171, 183, 226) . JCV infection may recruit HIV-infected macrophages into a demyelinated lesion, which then leads to a localized HIV encephalitis. Alternatively, uninfected macrophages may become infected by HIV after they are recruited into the nervous system. It is unclear whether the extent of these lesions can be explained by some degree of cytolytic synergy occurring with coinfection of the brain by both JCV and HIV (214) . Except for the macrophage ingress, inflammatory infiltrates are seldom seen in patients with PML. When lymphocytic perivascular cuffing and parenchymal accumulation are present, the course of the disease tends to be protracted, with periods of remission (105, 110, 174 61 ically confirmed and 40 virologically and pathologically confirmed cases of non-AIDS-associated PML and categorized the neurological signs and symptoms at onset and during disease progression. Visual deficit was the most common presenting sign, present in 35 to 45% of cases. Of the visual deficits, homonymous hemianopsia (loss of vision for one-half the visual field in each eye) was the most common. Interestingly, 6 to 8% of the patients were cortically blind at the time of diagnosis, indicating bioccipital pathology. Motor weakness was the initial sign in 25 to 33% of cases, though by the time the diagnosis was made, hemiparesis or hemiplegia was present in nearly all patients. A change in mentation, which included personality change, difficulty with memory, emotional lability, and frank dementia, was the presenting sign in approximately one-third of cases and eventually involved most patients.
Berger et al. (20) also found that hemiparesis, visual impairment, and altered mentation were the three most common initial manifestations as well as the most frequent signs during the course of AIDS-related PML. In their series of 28 patients, motor weakness, found in almost half of the cases, was the most common presenting symptom. Almost all patients went on to develop a spastic hemiparesis. Visual loss and mental status changes each accounted for approximately 25% of the initial manifestations. A small number of patients present with signs and symptoms referable to the posterior fossa, i.e., ataxia, dysmetria, and dysarthria, which usually indicate involvement of the white matter of the cerebellum and brainstem (100, 162) . Other signs and symptoms associated with PML include headache, vertigo, seizures, sensory deficits, parkinsonism, aphasia, and neglect syndromes (20, 28) . In some cases, the coexistence of HIV encephalitis could have accounted for some of the symptoms. Spinal cord involvement is rare (16) .
Diagnostic testing. Neuroimaging is by far the most useful tool in investigating a patient with PML. On a computerized tomography (CT) scan, the demyelinating lesions appear as subcortical hypodensities with a propensity for the parietooccipital area that respect the grey-white junction of the cortex and do not follow a vascular distribution (24, 43) . In general, no mass effect is noted, although rare exceptions have been reported on CT scanning and angiography (46, 166) . Single-dose intravenous contrast and delayed, doubledose contrast CT scanning as a rule usually fail to enhance lesions. Exceptions to this have been reported (181) . Contrast enhancement is evidence of disruption of the bloodbrain barrier and should prompt the clinician to consider an alternative diagnosis or consider the presence of a second pathologic process in the vicinity of the demyelination. In a representative case, Shafran et al. (186) described a patient with CLL who had multiple hypodense contrast-enhancing lesions on CT scan. At autopsy, the hypodensities corresponded to areas of demyelination consistent with PML, while the -contrast-enhancing areas coincided with a dense perivascular leukemic infiltrate apparently related to invasion of the brain by CLL. There are rare cases of slight homogeneous contrast enhancement at the periphery of a demyelinating lesion not associated with a second pathologic process (83) . This is probably the CT scan equivalent of the small artery and vein dilatation seen on cerebral angiograms of some patients with PML (111) . The vascular dilatation remains unexplained.
MRI has proved to be very sensitive in detecting the demyelinating lesions of PML (83, 115, 132) which have altered signal characteristics in comparison with the surrounding white matter. MRI is superior to CT scanning in demonstrating not only the number but also the extent of the lesions (165) . Occasionally, the MRI scan will clearly demonstrate pathology when the CT scan is normal. MRI is vastly superior to CT scanning in detecting infratentorial lesions which are now more frequently recognized in patients with PML. Several cases of grey-matter involvement have also been recognized antemortem by using MRI. Gadolinium enhancement of lesions seen on MRI is distinctly rare in patients with PML.
There is one case of PML studied with positron emission tomography which revealed cortical hypometabolism of glucose in the same portion of a hemisphere in which there was a subcortical white-matter lesion (108) . While this case raised several interesting points on the relationship between white-matter pathology and its effect on grey-matter metabolism, positron emission tomography scanning at this time has no role in the diagnostic workup of a suspected PML patient.
Electroencephalography is both insensitive and nonspecific for PML, but it may corroborate the presence of a lesion seen on neuroimaging. Early in disease presentation, focal slowing in the theta to delta range may correspond to focal lesions seen by a CT or MRI scan. As the lesions spread and become multifocal, the electroencephalogram becomes diffusely slow (59) . Evoked potentials are sensitive to demyelinating processes, as has been extensively demonstrated with multiple sclerosis. There is little information on evoked potentials in the context of PML, but one case report found that brainstem auditory-evoked and somatosensory-evoked potentials could accurately localize a lesion in the posterior fossa that could not be seen on CT scan (116) . CSF findings are nonspecific, with most patients demonstrating a normal profile. A mild lymphocytic pleocytosis, which is rarely if ever over 25 leukocytes per ml, may be seen in 15% of cases. Total protein is mildly elevated in approximately 20 to 30% of cases, while myelin basic protein, IgG, and IgG/albumin indices have been reported to be increased in a few cases (152) . The primary utility of lumbar puncture in the setting of possible PML is to exclude the presence of other illnesses, including treatable infections.
The most reliable and accurate method for the diagnosis of PML remains brain biopsy in order to demonstrate the pathological hallmarks described. The techniques of in situ hybridization and immunocytochemistry add a further degree of specificity when the biopsy material is examined. In situ DNA-DNA hybridization is a method of annealing JCV DNA to complementary strands either in paraffin-embedded tissue or in frozen sections from biopsy samples. The probe may be either radiolabeled (52) or biotinylated (2, 3, 5, 92, 187) , which in either case allows for the morphologic identification of the infected cells. In immunocytochemistry, antibodies to both T antigen and the common polyomavirus capsid antigen are used to detect cells undergoing productive viral infection (31, 72, 77) . A colorimetric method is used to identify the infected cells. adding new insight into the natural history and pathogenesis of PML as discussed above.
PCR is an emerging technology that may have a role in the diagnosis of PML. Several groups have reported detecting JCV in brain biopsies, CSF, and in some cases the peripheral lymphocytes of patients with PML by using PCR (11, 87, 206, 220) . We have found that more than 80% of patients with brain biopsy-proven PML will have JCV DNA in their lymphocytes as detected by PCR. In contrast, none of a group of Parkinson's disease patients had circulating JCV DNA.
Interestingly, one prolonged (more than 4 years) survivor of PML who has had a stable course still has JCV genome present in his peripheral blood lymphocytes (208) . In addition to supporting the theory that JCV infection is spread hematogenously, PCR may also have some clinical utility as a noninvasive method of confirming the diagnosis of PML. We are currently pursuing this possibility. A summary of the clinical characterization of PML is outlined in Table 2 .
While the prognosis of patients with PML is very poor, i.e., an average survival of 9 months (158, 199) , the course of the disease appears to be related to the severity of the underlying immunosuppression. PML in the setting of the profound immunodeficiency seen with AIDS is usually rapidly and relentlessly progressive, leading to death in 2 to 4 months from the time of symptom presentation (20) . PML developing in the setting of immunosuppression with cytotoxic agents to prevent graft rejection may have a prolonged course lasting several years if the cytotoxic agents are withdrawn or decreased (181) . In addition, there have been several cases of PML that stabilized without medical intervention (86, 162, 185) . In some cases, no clear immunodeficiency could be documented (233) , while three cases involved patients with AIDS (21) . In most cases, a return to immunocompetence apparently led to clearance of the virus from the CNS. In one case of prolonged survival, the pathology at the time of death no longer involved oligodendroglial or astrocytic infection (167) , again suggesting that the virus had been cleared from the CNS. These patients offer hope that JCV infection may be abrogated by effective antiviral or immunomodulatory therapy.
Host Factors in the Development of PML Approximately 10% of children between the ages of 1 and 5 years demonstrate antibody to JCV. By age 17 years, 65% of adolescents will have seroconverted, and the adult population in some urban areas shows as high as 92% seroconversion (217) . Primary exposure is not associated with any known clinical manifestations. Prior to the AIDS epidemic, the peak incidence of PML occurred during the sixth decade. This suggests that primary exposure to JCV occurs in most people during the first two decades of life and then is reactivated in those who later develop PML. A lack of IgM antibody directed at JCV in the presence of a preexisting IgG antibody to JCV is found in most cases of people with PML, again suggesting that the virus that causes demyelination originates from reactivation of a latent infection rather than from primary exposure (23, 217) . In most cases, the JCVdirected IgG titers do not rise during the course of the illness and are absent from the CSF (99, 215), although exceptions have been reported (109) . The vast majority of patients with PML have some degree of underlying cellular immunodeficiency that apparently allows for reactivation of infection. Prior to 1980, Hodgkin's disease and CLL were the underlying conditions most frequently associated with PML (173). (20, 111) . Up to 3.8% of all cases of AIDS will develop PML, a rate higher than that for other immunodeficient states (20, 111, 196) . This rate may reflect the more profound immune suppression associated with AIDS. There has also been the suggestion of a possible direct interaction between HIV type 1 and JCV proteins (70, 201) . Polyclonal gammopathies are frequently seen with HIV infection and reflect the loss of T-cell modulation of B cells. The possible role of B-cell activation in the pathogenesis of PML is discussed below. In a study of seven patients with PML, in vitro lymphocyte proliferation in response to mitogen stimulation was blunted, suggesting a generalized depression of cell-mediated immunity as expected (227) . Cellular immunity directed specifically against JCV was assessed by measuring the production of leukocyte migration inhibitory factor from lymphocytes in response to JCV antigens. Production of this factor was normal in response to JCV antigens in non-PML patients. In PML patients with cellular immunodeficiency, the factor was absent, suggesting that in addition to the generalized immunodeficiency, there is a selective deficiency in the cellular response to JCV in patients who develop PML. The further observation that both pregnant women (41) and patients who have been immunosuppressed (67) In what cell-type is JCV latent? This issue remains unresolved, but current research has questioned whether JCV could be latent in brain cells from healthy individuals. Brains from immunosuppressed and nonimmunosuppressed patients without PML do not demonstrate early or late viral antigens by immunocytochemistry, nor do they demonstrate the presence of viral genome by in situ hybridization (90) . Recently, PCR technology has been used to demonstrate the presence of viral DNA in brain tissue from PML patients (12, 206) . However, in two studies, PCR did not amplify the JCV DNA in healthy brain tissue or tissue of subjects with other neurological processes (87, 206) . In total, these observations suggest that JCV remains latent outside the CNS and then gains access to the nervous system some time during immunosuppression. As noted above, JCV may be shed in the urine of pregnant women and immunosuppressed renal transplant patients, which suggests that the virus is latent in the genitourinary tract. While one study found that 10% of healthy subjects have nonintegrated JCV DNA in renal tissue (36), a second study found no evidence of JCV DNA in kidney tissue from non-PML-affected patients (81) . Using dot blot hybridization, Grinnell et al. (81) found viral genomes in the kidney of five of seven patients. In the same study, they also found JCV DNA in lung, liver, lymph node, and spleen cells in three of these patients, two of whom were children with combined immunodeficiency syndromes, which suggests that widespread dissemination of the viral genome can occur in the setting of severe dysimmunity. Hematogenous spread to the CNS is supported by the multifocal nature of the demyelinating lesions as well as their location near the grey-white junction where the end arterioles of the cerebrovascular tree are found. In our laboratory, we have used PCR to demonstrate the presence of JCV genome in peripheral lymphocytes of PML-affected subjects, again supporting the notion of hematogenous spread of the virus via lymphocytes.
TREATMENT OF PML
Effective therapy of PML, whether specific antiviral therapy directed at JCV or attempts to enhance cellular immunity, remains elusive. On the basis of anecdotal reports and a small series of reported cases of PML, a variety of treatment regimens have been proposed (Table 3) . However, no therapeutic regimens have been studied in a randomized, double-blind fashion. The need for a large formal study of any treatment regimen suggested for this illness is highlighted by the observations that PML may remain quite stable for long periods and may even remit in the rare patient (21, 57, 105, 158, 167, 190) . Before the recent increase in the prevalence of PML as the result of HIV-1 infection, the disease was sufficiently rare to tender a study of this nature impractical. With an estimated prevalence of 3.8% in patients with HIV-1 infection (20), some institutions with large populations of patients with AIDS may treat large enough numbers of patients with PML to perform such studies without having to resort to a multi-institutional study.
Nucleoside Analogs Nucleoside analogs interfere with the synthesis of DNA and have established efficacy in the treatment of some viral diseases. Among these nucleic acid base analogs are adenine arabinoside, iododeoxyuridine, and acyclovir for herpes simplex virus, ganciclovir for cytomegalovirus, and zidovudine (AZT), dideoxycytidine, and dideoxyinosine for HIV-1 infection. These agents often have antiviral activities and may be incapable of inhibiting the replication of other viruses in the same family. Several nucleoside analogs have been used in the treatment of PML with various degrees of success (Table 4) .
Despite earlier failures (33) , therapeutic trials with cytosine arabinoside, a drug chiefly used in the treatment of myeloproliferative disorders, suggested that the drug is effective (17, 42) . Bauer and colleagues (17) reported the use of cytosine arabinoside administered intravenously at 60 mglm2/day and intrathecally at 10 mg/M2 in a 36-year-old man with PML complicating CLL. Within 48 h of the initiation of therapy, improvement in his dysarthria and hemiparesis was noted. Improvement continued during 10 months of follow-up. Marriott et al. (133) described marked improvement within 6 weeks and continued improvement over 18 months after the initiation of cytosine arabinoside at 2 mg/kg/day five times every 3 weeks in a 52-year-old woman whose PML complicated sarcoidosis. Buckman and Wiltshaw (30) noted a resolution of neurological symptoms in a 46-year-old woman with Hodgkin's disease and suspected PML (never proven by biopsy) who received both intravenous and intrathecal cytosine arabinoside. O'Riordan et al. (154) described minimal neurological improvement in a 51-year-old woman with PML complicating non-Hodgkin's lymphoma that was in complete remission. She received intravenous cytosine arabinoside at 2 mg/kg of body weight per day for 5 days repeated every 21 days. However, when VOL. 5, 1992 on October 60 mg/m2/day for 5 days and 100 mg/m2 intrathecally on one occasion. Some case reports suggest a lack of efficacy of cytosine arabinoside administered either solely intravenously (33, 193) or in combination with intrathecal therapy (212) .
Other nucleoside analogs appear to have met with less success than cytosine arabinoside in the treatment of PML. Wolinsky et al. (229) 
Interferons
The interferons have been proposed as potential therapeutic agents in the treatment of PML because of their antiviral activity. Their antiviral response appears to be directly proportional to their ability to stimulate natural killer cells (210) . Alpha interferon has established efficacy in the treatment of other papovaviruses and has become an accepted form of therapy for resistant genital warts that result from infection with various human papillomaviruses (HPV) (221) . Alpha interferon has also been demonstrated to be effective against HPV whether administered topically, intralesionally, or systemically (221) . Certain strains of HPV, such as HPV 16 and 18, appear more resistant to alpha interferon than other strains (184) . Alpha interferon has also demonstrated efficacy in the treatment of laryngeal papillomatosis, a disorder that also results from HPV infection. While the genetic homology between HPV and JCV is slight, alpha interferon has also shown activity against SV40, which is closely related to JCV and has been implicated in several rare cases of PML (223), although the identification of SV40 rather than JCV in these cases is not unequivocal. Pretreatment of African green monkey CV-1 cells with alpha interferon inhibits the accumulation of SV40 mRNAs and SV40 T protein. Not surprisingly SV40-transformed mouse embryo fibroblasts, C57BL/6, are susceptible to lysis by natural killer cells (62) .
In light of these observations regarding alpha interferon and the selective defect in alpha interferon production by HIV-1-infected monocytes (71) (Fig. 6) . At least three patients have remained clinically stable for periods of 6 months following the initiation of alpha interferon 2A. Progression of the disease despite alpha interferon 2A therapy has been observed in four patients. Three of these patients had advanced and rapidly progressive neurological disease when they were enrolled in the experimental protocol. (27) . If have been treated with AZT in various doses. No correlation with neurological recovery has been noted. Furthermore, none of our patients who showed dramatic clinical recovery and whose MRI showed resolution of brain lesions were on AZT at the time of recovery.
DISCUSSION
The early observation that JCV caused a common viral infection in the population but could multiply efficiently only in the oligodendrocyte of the CNS created a paradox in understanding the pathogenesis of PML. Over the 20 years since the isolation of JCV in 1971 (161) , experiments have been designed to determine the mechanisms that explain how a virus could be so widespread in the population but maintain such a narrow host range and selectively target the specialized, myelin-producing cell in the human brain. What has emerged from these studies are two dominant areas of investigation that have become central to the understanding of this virus-induced demyelinating disease: the molecular control of JCV gene expression and replication and the establishment and reactivation of viral latency.
Molecular Control of Viral Gene Expression
Understanding the effects of host cell-restricted JCV gene expression is essential for understanding the establishment of JCV latency preceding the development of PML. The molecular basis for this restriction centers on the noncoding or regulatory sequences of the viral genome. Variations in the nucleotide sequences are found to occur predominantly within the regulatory region (51, 80, 117, 170, 231) . Some differences in nucleotide sequences of the regulatory region are found in JCV isolates cloned from different brains (136) . These differences, however, do not seem to affect the ability of the virus to induce PML. Major alterations occur in the nucleotide sequences of the regulatory region of JCV isolates cloned from kidney cells. The differences in the regulatory region sequences between brain and kidney isolates have been shown to occur in virus cloned from the same patient with PML (117) . That JCV may have a parent or archetypal DNA sequence that evolves into a brain-specific strain has been suggested by the analysis of regulatory sequences with multiple insertions (231) . Following alterations and deletions of these insertions, different viral strains with different cell specificities could have evolved. These observations have yet to be tested. The regulatory region of the JCV strain responsible for primary infection may determine which host cells undergo initial JCV infection. Therefore, the JCV strains responsible for primary infection would determine whether and where JCV latency occurs, e.g., in the kidney or elsewhere. Changes in the nucleotide sequences within the regulatory region during initial viral replication could extend the host range and cell types in which JCV persistence could be established. The role of the regulatory region in JCV latency is being studied by cloning and sequencing PCR amplification products of viral genomes in latently infected cells. Using these techniques, we may soon be able to determine the significance of certain DNA sequences in the regulatory region in establishing latency.
Host cell restriction of JCV expression also occurs at the level of viral mRNA transcription and depends on the ability of host cell transcription factors to recognize elements within the JCV regulatory region (60) . When a reporter gene vector, CAT, was used, transcription from the JCV regulatory region occurred only in specific cells (104, 107) . Specific binding to nucleotide sequences within the JCV regulatory region has been described for a number of host cell nuclear proteins, including NF-1, which is found in human fetal brain cells in DNA binding experiments (1, 6, 107) . The result of protein binding of a combination of both positive and negative nuclear transcription factors that recognize specific nucleotide sequences could affect viral expression.
Primary and Latent JCV Infections
Primary JCV infection appears to be asymptomatic, making prospective studies difficult to perform. An understanding of the primary infection has important implications for understanding JCV pathogenesis, since the cell types initially infected are candidates for virus latency. Viruses not directly injected into the bloodstream by arthropod vectors undergo an initial replication cycle in cells proximal to the portal of entry. Since the portal of entry for JCV is unknown, the cell types supporting initial virus replication remain undefined. We do know that JCV DNA has been found in spleen, lymph node, kidney, and lung cells in two children with combined immunodeficiency disease who developed PML during what was thought to be primary JCV infection (81) . Whether primary JCV infection in the immunocompetent host results in systemic spread of the virus is unknown.
Since JCV latency is most likely established during primary infection, determination of the sites of persistence of the viral genome will provide the minimum number of cell types undergoing primary infection. Evidence reviewed here suggests that JCV is latent in two extraneural sites but is probably not present in the brain. JCV has not been detected in neuroglial cells of any healthy brain using a variety of techniques including cocultivation with susceptible glial cells, in situ DNA hybridization with radiolabeled probes, electron microscopy, and PCR amplification (28, 206) . These studies suggest that JCV does not reach the brain during primary infection and that spread to the nervous system must follow reactivation at other sites.
Evidence of JCV infection in the kidney and in lymphocytes has been described. JCV has been isolated from the urine of immunosuppressed patients with and without PML, and viral DNA has been detected in kidney cells by in situ hybridization. For several reasons, reactivation of latent JCV in the kidney is of uncertain significance in the pathogenesis of PML. JCV cloned or isolated from brain requires adaptation before significant viral replication will occur in kidney cultures. Nucleotide sequences within the JCV regulatory region differ in viruses isolated or cloned from brain and kidney cells, even in those from the same patient (117) . Finally, JCV DNA is not always in the kidney cells from patients with PML. Lymphocytes are a second extraneural site of JCV infection. B lymphocytes containing JCV DNA and virion capsid antigens are present in the bone marrow and brain cells of PML patients. JCV DNA is present in peripheral blood lymphocytes of patients with PML, and JCV replication may occur in B-lymphocyte cell lines (93, 122) . Although other sites of JCV latency are unknown, the techniques used in the experiments described above are not, generally, adequately sensitive to detect the low copy number of JCV genomes expected to occur in latently infected cells. PCR amplification technology offers the needed sensitivity. PCR amplification of DNA If JCV persists in B lymphocytes, the biology of B-cell growth and development (27, 45, 225) (27, 225) . Further studies are needed to determine the frequency of JCV DNA in peripheral blood lymphocytes in PML-and non-PMLaffected individuals and to identify those cell types containing JCV DNA. Macrophages are the predominant cellular immune response to JCV neuroglial infection. The mechanism of macrophage recruitment into demyelinating lesions is unknown and deserves further study. JCV-specific cellular immune studies in a small number of patients suggest that T-cell cytotoxicity is present despite the presence of immunodeficiency. JCV clones produced for molecular biological studies provide a means of obtaining sufficient viral antigens for future studies of JCV-specific cellular immunity in PML patients and controls. The failure of cytotoxic T cells to clear JCV infection may be related to the inability of JCV-infected glial cells to express viral antigens with major histocompatibility complex class 1 cytes from crossing the blood-brain barrier in experimental animals, is one such treatment that has been instituted as a result of our increased knowledge of PML pathogenesis (27) . Gamma interferon, which increased major histocompatibility complex antigen expression by virus-infected glial cells, may improve the effector functions of host T cytotoxic cells by enhancing recognition of latent JCV and could be used prophylactically in patients at risk of developing PML. Until antiviral drugs that target JCV in its multiplication cycle become available, immunomodulating agents that reflect our understanding of the pathogenesis of PML appear to offer the best approach to treatment.
